Browse Studies — Arctuva

Phase 3

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patie…

Metastatic Dedifferentiated LiposarcomaMetastatic Undifferentiated Pleomorphic SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06422806

Phase 1

A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma

The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, re…

Well Differentiated LiposarcomaDedifferentiated LiposarcomaLiposarcoma+6 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06843967

Phase 1

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sar…

Metastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Myxofibrosarcoma+9 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05711615